Concepedia

Fabrice Le Gall

FL

Statistics

Publications

14

Citations

1.1K

H-Index

14

Active since

1998

Affiliations

Affimed Therapeutics (Germany)(Current)

German Cancer Research Center

Heidelberg University

Fabrice Le Gall is an author at Affimed Therapeutics (Germany) specializing in immunology, life sciences, and immunotherapy.

Publications per year

1998–2015

14

Publications

14

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30<sup>+</sup>tumor cells

Uwe Reusch, Carmen Burkhardt, Ivica Fucek et al. · mAbs · 2014 · 159 citations · Full text

, , +17

Di‐, tri‐ and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

Fabrice Le Gall, Sergey M. Kipriyanov, Gerhard Moldenhauer et al. · FEBS Letters · 1999 · 128 citations · Full text

, , +17

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19<sup>+</sup>tumor cells

Uwe Reusch, Johannes Duell, Kristina Ellwanger et al. · mAbs · 2015 · 127 citations · Full text

, , +17

Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma

Sergey M. Kipriyanov, Björn Cochlovius, Holger Schäfer et al. · The Journal of Immunology · 2002 · 90 citations · Full text

, , +17

Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody

Fabrice Le Gall, Uwe Reusch, Melvyn Little et al. · Protein Engineering Design and Selection · 2004 · 82 citations

, , +17

1–5 of 14